US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

10.64 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >
News headline image
Silence Therapeutics to Participate in Three September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial ↗
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its... 
Via MarketBeat
News headline image
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
From Silence Therapeutics plc
Via Business Wire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
From Silence Therapeutics plc
Via Business Wire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
Top movers in Thursday's session ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Top movers in Friday's session ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 Next >